RSV, Merck
Clesrovimab (MK-1654) is an investigational, extended half-life monoclonal antibody (mAb) developed as a passive immunization for the prevention of RSV. Clesrovimab is designed to be administered ...
Clesrovimab scored on several endpoints, showing an ability to protect infants against the virus in their first RSV season.
Clesrovimab (MK-1654), an Investigational RSV Monoclonal Antibody, Significantly Reduced Incidence of RSV Disease and ...
The drug clesrovimab also helped reduce RSV associated hospitalizations by 84.2% compared to placebo, Merck said.
In the study, clesrovimab (MK-1654) significantly reduced the incidence of RSV disease and hospitalisations in healthy ...
New data released by Merck suggests AstraZeneca and Sanofi’s Beyfortus, the monoclonal antibody injection that protects ...
Wall Street promptly began trying to weigh the compound’s marketplace odds after Merck & Co. Inc. detailed positive data from the phase IIb/III trial known as MK-1654-004 with clesrovimab, an ...
Respiratory virus season is underway, but Washington is more prepared than it was last year to protect against some severe ...
COVID-19, influenza and RSV are the main threats between October and May. There are vaccines for all three viruses, so you ...
A new study in The Lancet Infectious Diseases describes the genotypic and phenotypic characteristics of respiratory syncytial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback